Skip to main content

Table 3 Current and lifetime substance use of the overall study sample and by smoking status

From: Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial

Characteristic Overall (N = 150)
%/M ± SD/ Md (Q1, Q3)
Smokers (n = 126)
n(%)/M ± SD/ Md (Q1, Q3)
Non-smokers (n = 24)
n(%)/M ± SD/ Md (Q1, Q3)
p
Urine drug screen
 Any drug 74(49.3) 65(51.6) 9(37.5) .20
 Opiates 37(24.7) 32(25.4) 5(20.8) .63
 Cocaine 44(29.5) 41(32.5) 3(12.5) .04
 Benzodiazepines 23(15.3) 19(15.1) 4(16.7) .76
 Amphetamines 17(11.3) 14(11.1) 3(12.5) .73
Alcohol and drug use
 Past 30 days use
 Alcohol 47(31.3) 44(34.9) 3(12.5) .02
 Alcohol intoxication 36(24.0) 36(28.5) 0(0.0) .002
 Cannabis 44(29.3) 38(30.1) 6(25) .61
 Methadone 148(98.6) 124(98.4) 24(100) .53
 Opiates 33(22.0) 28(22.2) 5(20.8) .88
 Cocaine 36(24.0) 35(27.7) 1(4.1) .01
 Barbiturates 6(4.0) 4(3.1) 2(8.3) .23
 Hallucinogens 5(3.3) 5(3.9) 0(0) .32
 Inhalants 1(0.6) 1(0.7) 0(0) .66
 Lifetime use (years)
 Alcohol 2(0, 7) 2(0, 9.75) 0(0, 3.7) .11
 Alcohol intoxication 1(0, 6.7) 1.5(0 7.0) 0(0, 2) .04
 Cannabis 3.5(0, 15) 4.5(0, 15) 0(0, 22.5) .80
 Methadone 8(3, 12.7) 7(2.25, 15) 10.5(5.25, 23.5) .08
 Opiates 1(0, 5) 1(0, 5) 2(0, 7) .50
 Cocaine 4.5(0, 14.5) 5(0, 15) 2(0, 8.5) .19
 Barbiturates 0(0, 0) 0(0, 0) 0(0, 0) .07
 Hallucinogens 0(0, 1) 0(0, 1) 0(0, 0.25) .87
 Inhalants 0(0, 0) 0(0, 0) 0(0, 0) .19
  1. Note: M mean, SD standard deviation, Md median, Q1 quartile 1, Q3 quartile 3